Related Experiment Video
Updated: May 10, 2026
Closure of a Patent Foramen Ovale (PFO): An Intervention Sequence
Published on: December 23, 2022
[Percutaneous closure of patent ductus arteriosus: short term results]
Yüksel Kaya1, Mustafa Orhan Bulut, Mustafa Yurtdaş
1Department of Cardiology, Kafkas University Faculty of Medicine, Kars, Turkey. dryuksel_kaya@yahoo.com.tr.
Insights
Percutaneous closure of patent ductus arteriosus (PDA) using Amplatzer devices is safe and effective. This study shows high success rates and low complications in pediatric and adult patients undergoing PDA closure.
Area of Science:
- Cardiology
- Interventional Cardiology
- Pediatric Cardiology
Background:
- Patent ductus arteriosus (PDA) is a congenital heart defect requiring intervention.
- Percutaneous closure offers a less invasive alternative to surgical repair.
Purpose of the Study:
- To assess the short-term outcomes of percutaneous PDA closure.
- To evaluate the efficacy and safety of Amplatzer Ductal Occluder (ADO-1, ADO-2) and Amplatzer Septal Occluder (ASO) devices.
Main Methods:
- Retrospective analysis of 48 pediatric and adult patients.
- Transthoracic echocardiography (TTE) and aortography for pre- and post-procedure assessment.
- Percutaneous closure performed via anterograde or retrograde routes under fluoroscopy.
Main Results:
- High procedural success rate (97.9%) with Amplatzer devices (ADO-1, ADO-2, ASO).
- Complete closure observed in 38 patients immediately post-procedure.
- Minimal residual shunts detected in a small percentage of patients at 24 hours and 3 months.
Conclusions:
- Transcatheter closure of PDA using ADO-1 and ADO-2 devices demonstrates low morbidity and mortality.
- These devices are highly successful in selected pediatric and adult patients requiring PDA closure.
Objectives:
To evaluate short term results of percutaneous patent ductus arteriosus (PDA) closure in a cohort of pediatric and adult patients following closure with the Amplatzer Ductal Occluder (ADO-1 and ADO-2) and Amplatzer Septal Occluder (ASO) devices.
Study Design:
A total of 48 patients (17 male and 31 female; range 3 to 39 years) were included in this study. All patients were evaluated with transthoracic echocardiography (TTE) before intervention. Percutaneous closure was performed under fluoroscopy through anterograde or retrograde route. Aortagraphy was performed to measure and classify the ductus arteriosus. Residual shunt through ductus was controlled by aortography at the tenth minute and by TTE 24 hours and three months after the procedure.
Results:
The released device was ADO-1 in 25 patients (51.2%), ADO-2 in 22 patients (45.8%), and ASO in one patient. Mean follow-up was 13.2 months. In 97.9% of patients, the occluder was placed into the ductus without any complication. In one patient, the device embolized to the left pulmonary artery during implantation. Aortography performed ten minutes after the procedure showed complete closure in 38 patients without residual defect. TTE revealed trace amounts of residual shunt within the device in two patients, flow around the device in two patients 24 hours after implantation, and residual shunt in only one patient three month after intervention.
Conclusion:
Transcatheter closure of PDA with ADO-1 and ADO-2 devices has low morbidity and mortality with high rates of success in selected patients.
